Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Rafael Holdings Reports Second Quarter Fiscal Year 2019 Results

      Rafael Holdings holds commercial real estate assets and interests in two clinical stage pharmaceutical companies.  The pharmaceutical holdings consist of interests in Rafael Pharmaceuticals, Inc. and a majority stake in Lipomedix Pharmaceuticals Ltd., both of which are focused on development and commercialization of drugs in the oncology space.  For more information, visit www.rafaelholdings.com (PRNewsfoto/Rafael Holdings, Inc.)

      News provided by

      Rafael Holdings, Inc.

      Mar 12, 2019, 16:30 ET

      Share this article

      Share this article


      NEWARK, N.J., March 12, 2019 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE American: RFL), reported revenue of $1.0 million and a loss per share of $0.08 for the second quarter of its 2019 fiscal year, the three months ended January 31, 2019. 

      Highlights

      • Rafael Holdings exercised a warrant and now holds a majority of the outstanding equity of Rafael Pharmaceuticals, Inc., (Rafael Pharma), a clinical stage, metabolic oncology-therapeutics company;
      • Rafael Pharma announced that the European Medicines Agency has granted orphan drug designation to devimistat (CPI-613®) for the treatment of metastatic pancreatic cancer and relapsed or refractory acute myeloid leukemia (AML);
      • Rafael Pharma initiated the following clinical trials of devimistat:
        • Phase 3 in combination with modified FOLFIRINOX (mFFX) as a first-line therapy for patients with metastatic adenocarcinoma of the pancreas;
        • Phase 3 in combination with high dose cytarabine and mitoxantrone for patients ≥ 60 years of age with relapsed or refractory AML;
        • Phase 2 for patients with relapsed or refractory Burkitt Lymphoma;
        • Phase 2 in combination with (mFFX) for patients with localized borderline and unresectable pancreatic cancer.

      Remarks by Howard Jonas, Chairman and CEO of Rafael Holdings

      "This quarter, we significantly increased our investment in Rafael Pharmaceuticals, purchasing a majority of the shares outstanding inclusive of interests held by minority holders in our subsidiaries.

      "Rafael Pharma made excellent progress on its clinical trial program for difficult to treat cancers including the initiation of pivotal phase 3 trials of devimistat for patients with advanced metastatic pancreatic cancer and AML.

      "LipoMedix Pharmaceuticals has initiated a phase 1b trial to identify the optimal dose, safety and efficacy of its lead compound Promitil® in combination with external beam radiotherapy in patients with advanced cancer requiring radiotherapy for inoperable primary tumors or metastatic disease.

      "On the real estate side of our business, we continued our effort to monetize our properties including our 20-story commercial property and associated garage in Newark, New Jersey."

      About Rafael Holdings, Inc.:
      Rafael Holdings holds commercial real estate assets and interests in two clinical stage, oncology focused pharmaceutical companies.  The real estate holdings include properties in Newark and Piscataway, New Jersey and Jerusalem, Israel.  The pharmaceutical holdings consist of interests in Rafael Pharmaceuticals, Inc. and a majority stake in Lipomedix Pharmaceuticals Ltd., both of which are focused on development and commercialization of drugs in the oncology space. 

      RAFAEL HOLDINGS, INC.

      CONSOLIDATED BALANCE SHEETS

      (in thousands, except share data)




      January 31,



      July 31,




      2019



      2018




      (unaudited)



      (audited)


      ASSETS







      CURRENT ASSETS:







      Cash and cash equivalents


      $

      14,769



      $

      15,803


      Trade accounts receivable, net of allowance for doubtful accounts of $91 and $82 at January 31, 2019 and July 31, 2018, respectively



      356




      287


      Marketable securities



      —




      24,701


      Due from Rafael Pharmaceuticals



      —




      3,300


      Prepaid expenses and other current assets



      588




      421


      Total current assets



      15,713




      44,512











      Property and equipment, net



      49,378




      50,113


      Investments – Rafael Pharmaceuticals



      70,018




      13,300


      Investments – Other Pharmaceuticals



      2,000




      2,000


      Investments – Hedge Funds



      4,166




      4,218


      Deferred income tax assets, net



      15




      —


      Patents



      324




      324


      In-process research and development



      1,327




      1,327


      Other assets



      1,225




      1,126


      TOTAL ASSETS


      $

      144,166



      $

      116,920











      LIABILITIES AND STOCKHOLDERS' EQUITY









      CURRENT LIABILITIES:









      Trade accounts payable


      $

      535



      $

      367


      Accrued expenses



      650




      500


      Other current liabilities



      20




      24


      Total current liabilities



      1,205




      891











      Due to/from related parties



      —




      276


      Convertible debt, net of discount - Related Party



      14,934




      —


      Other liabilities



      195




      188











      TOTAL LIABILITIES



      16,334




      1,355











      COMMITMENTS AND CONTINGENCIES


















      STOCKHOLDERS' EQUITY









      Class A common stock, $0.01 par value; 35,000,000 shares authorized, 787,163 shares issued and outstanding as of January 31, 2019 and July 31, 2018



      8




      8


      Class B common stock, $0.01 par value; 200,000,000 shares authorized, 13,133,069 and 11,762,346 shares issued and outstanding as of January 31, 2019 and July 31, 2018, respectively



      119




      118


      Additional paid in capital



      117,269




      103,636


      Accumulated deficit



      (2,649)




      (1,108)


      Accumulated other comprehensive income



      4,080




      4,043


      Total stockholders' equity



      118,827




      106,697


      Noncontrolling interests



      9,005




      8,868


      TOTAL EQUITY



      127,832




      115,565











      TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY


      $

      144,166



      $

      116,920


      RAFAEL HOLDINGS, INC.

      CONSOLIDATED AND COMBINED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME

      (unaudited, in thousands, except share data)




      Three Months Ended
      January 31,



      Six Months Ended
      January 31,




      2019



      2018



      2019



      2018















      REVENUE:













      Rental – Third Party


      $

      306



      $

      298



      $

      689



      $

      685


      Rental – Related Party



      522




      489




      1,043




      994


      Parking



      189




      169




      420




      384


      Total Revenue



      1,017




      956




      2,152




      2,063



















      COSTS AND EXPENSES

















      Selling, general and administrative



      1,716




      1,343




      3,169




      3,079


      Research and development



      276




      —




      649




      —


      Depreciation and amortization



      431




      429




      860




      853


      Loss from Operations



      (1,406)




      (816)




      (2,526)




      (1,869)


      Interest income, net



      767




      2




      868




      4


      Net gain resulting from foreign exchange transactions



      —




      107




      —




      118


      Net loss on equity investments



      —




      —




      —




      (107)


      Gains on sales of marketable securities, net



      103




      —




      330




      —


      Unrealized loss on Investments – Hedge Funds



      (148)




      —




      (52)




      —


      Gain on disposal of bonus shares



      —




      —




      —




      246


      Loss Before Income Taxes



      (684)




      (707)




      (1,380)




      (1,608)


      (Provision for) benefit from income taxes



      (17)




      (15)




      14




      (8,443)


      Net Loss



      (701)




      (722)




      (1,366)




      (10,051)


      Net income (loss) attributable to noncontrolling interests



      320




      (176)




      136




      (176)


      Net Loss attributable to Rafael Holdings, Inc.


      $

      (1,021)



      $

      (546)



      $

      (1,502)



      $

      (9,875)



















      OTHER COMPREHENSIVE INCOME

















      Foreign currency translation adjustments


      $

      80



      $

      68



      $

      2



      $

      78


      Total Comprehensive Loss



      (621)




      (654)




      (1,364)




      (9,973)


      Comprehensive income attributable to noncontrolling interests



      15




      19




      23




      19


      Total Comprehensive Loss attributable to Rafael Holdings, Inc.


      $

      (636)



      $

      (673)



      $

      (1,387)



      $

      (9,992)



















      Loss Per Share:

















      Basic and diluted


      $

      (0.08)



      $

      (0.04)



      $

      (0.12)



      $

      (0.79)



















      Weighted average number of shared used in calculation of loss per share:

















      Basic and diluted



      13,489,583




      12,541,998




      12,634,389




      12,541,998


        

      RAFAEL HOLDINGS, INC.

       CONSOLIDATED AND COMBINED STATEMENTS OF CASH FLOWS

      (unaudited, in thousands, except share data)




      Six Months Ended
      January 31,




      2019



      2018






      Operating activities







      Net loss


      $

      (1,366)



      $

      (10,051)


      Adjustments to reconcile net loss to net cash provided by (used in) operating activities:









      Depreciation and amortization



      860




      853


      Deferred income taxes



      (15)




      8,837


      Interest income on Series D Convertible Note



      (848)




      —


      Net gain on sale of marketable securities



      (330)




      —


      Unrealized loss on investments – Hedge Funds



      52




      —


      Provision for doubtful accounts



      9




      —


      Realized gain on disposal of bonus shares



      —




      (246)


      Non-cash compensation



      172




      606


      Amortization of debt discount



      5




      —


      Interest in the equity of investments



      —




      439


      Change in assets and liabilities:









      Trade accounts receivable



      (78)




      38


      Other current assets and prepaid expenses



      (186)




      (60)


      Other assets



      (82)




      (260)


      Accounts payable and accrued expenses



      296




      77


      Other current liabilities



      39




      (15)


      Due to/from related parties



      588




      (202)


      Other liabilities



      (15)




      25


      Net cash (used in) provided by operating activities



      (899)




      41











      Investing activities









      Purchases of property and equipment



      (58)




      (728)


      Proceeds from sale and maturity of marketable securities, net



      25,031




      —


      Investment in Rafael Pharmaceuticals



      (55,870)




      —


      Net cash used in investing activities



      (30,897)




      (728)











      Financing activities









      Contribution from noncontrolling interest of consolidated entity



      4,587




      —


      Repayment of Loan from Rafael Pharmaceuticals



      3,300




      —


      Proceeds from exercise of options



      163




      —


      Proceed from sale of shares



      7,777




      —


      Proceeds from convertible notes payable - Related Party



      15,000




      —


      Cash advances from IDT Corporation, net of repayments



      —




      900


      Net cash provided by financing activities



      30,827




      900


      Effect of exchange rate changes on cash and cash equivalents



      (65)




      39


      Net (decrease) increase in cash and cash equivalents



      (1,034)




      252


      Cash and cash equivalents at beginning of period



      15,803




      11,756


      Cash and cash equivalents at end of period


      $

      14,769



      $

      12,008











      Supplemental Schedule of Non-Cash Financing and Investing Activities









      Adoption effect of ASU 2016-01


      $

      39




      —


      Beneficial conversion feature of convertible debt – related party


      $

      71




      —


      Debt and accrued interest converted to Series D Preferred Stock


      $

      10,848




      —


      Related Party deposit utilized to purchase Class B Common Stock


      $

      864




      —


      Cash payments made for interest & taxes



      —




      —


        

      SOURCE Rafael Holdings, Inc.

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.